Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NXP-800 by Nuvectis Pharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
NXP-800 is under clinical development by Nuvectis Pharma and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...